Search

Tan V. Mai

Examiner (ID: 12217, Phone: (571)272-3726 , Office: P/2182 )

Most Active Art Unit
2193
Art Unit(s)
2301, 2306, 2787, 2183, 2302, 2182, 2786, 2193, 2121, 2124
Total Applications
3863
Issued Applications
3434
Pending Applications
94
Abandoned Applications
349

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 20192232 [patent_doc_number] => 20250268942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => ISOLATED IMMUNE CELL EXPRESSING A RECEPTOR, INTERLEUKIN-7, AND CHEMOKINE (C-C MOTIF) LIGAND 19 [patent_app_type] => utility [patent_app_number] => 19/193454 [patent_app_country] => US [patent_app_date] => 2025-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19193454 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/193454
ISOLATED IMMUNE CELL EXPRESSING A RECEPTOR, INTERLEUKIN-7, AND CHEMOKINE (C-C MOTIF) LIGAND 19 Apr 28, 2025 Pending
Array ( [id] => 20085505 [patent_doc_number] => 20250215441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-03 [patent_title] => ENGINEERED DNA MOLECULE FOR CODING RNA [patent_app_type] => utility [patent_app_number] => 19/083930 [patent_app_country] => US [patent_app_date] => 2025-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19083930 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/083930
ENGINEERED DNA MOLECULE FOR CODING RNA Mar 18, 2025 Pending
Array ( [id] => 20287200 [patent_doc_number] => 20250312443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-09 [patent_title] => LIPID COMPOSITION TARGETING ANTIGEN-PRESENTING CELLS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/048826 [patent_app_country] => US [patent_app_date] => 2025-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19048826 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/048826
Lipid composition targeting antigen-presenting cells and use thereof Feb 6, 2025 Issued
Array ( [id] => 19512088 [patent_doc_number] => 20240343774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING AND PROTECTING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS [patent_app_type] => utility [patent_app_number] => 18/758151 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758151 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/758151
Methods and compositions for treating and protecting against porcine reproductive and respiratory syndrome virus Jun 27, 2024 Issued
Array ( [id] => 19447321 [patent_doc_number] => 20240307451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION, AND CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/737778 [patent_app_country] => US [patent_app_date] => 2024-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18737778 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/737778
IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION, AND CHIMERIC ANTIGEN RECEPTOR Jun 6, 2024 Pending
Array ( [id] => 20213805 [patent_doc_number] => 12410449 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Endonuclease systems [patent_app_type] => utility [patent_app_number] => 18/669712 [patent_app_country] => US [patent_app_date] => 2024-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 95 [patent_no_of_words] => 51552 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18669712 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/669712
Endonuclease systems May 20, 2024 Issued
Array ( [id] => 20433425 [patent_doc_number] => 12503710 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => Base editing enzymes [patent_app_type] => utility [patent_app_number] => 18/653454 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 92 [patent_no_of_words] => 76562 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653454 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/653454
Base editing enzymes May 1, 2024 Issued
Array ( [id] => 19379446 [patent_doc_number] => 20240269316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NUCLEIC ACID SENSOR AGONIST COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/612893 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612893 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/612893
NUCLEIC ACID SENSOR AGONIST COMPOSITIONS AND USES THEREOF Mar 20, 2024 Pending
Array ( [id] => 19497907 [patent_doc_number] => 20240336925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES [patent_app_type] => utility [patent_app_number] => 18/597673 [patent_app_country] => US [patent_app_date] => 2024-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18597673 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/597673
Riboswitch modulated gene therapy for retinal diseases Mar 5, 2024 Issued
Array ( [id] => 19217829 [patent_doc_number] => 20240182533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND MICRORNA-29 AND THE TREATMENT OF MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 18/482526 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482526 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/482526
ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND MICRORNA-29 AND THE TREATMENT OF MUSCULAR DYSTROPHY Oct 5, 2023 Pending
Array ( [id] => 19464518 [patent_doc_number] => 20240318187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/477788 [patent_app_country] => US [patent_app_date] => 2023-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 115811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 239 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477788 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/477788
POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF Sep 28, 2023 Abandoned
Array ( [id] => 19389780 [patent_doc_number] => 20240279650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => Therapeutic Editing [patent_app_type] => utility [patent_app_number] => 18/474327 [patent_app_country] => US [patent_app_date] => 2023-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18474327 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/474327
Therapeutic Editing Sep 25, 2023 Pending
Array ( [id] => 19354308 [patent_doc_number] => 12054739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => Engineered retrons and methods of use [patent_app_type] => utility [patent_app_number] => 18/472824 [patent_app_country] => US [patent_app_date] => 2023-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 71 [patent_no_of_words] => 118157 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472824 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/472824
Engineered retrons and methods of use Sep 21, 2023 Issued
Array ( [id] => 19536937 [patent_doc_number] => 12129478 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-29 [patent_title] => Engineered adenosine deaminases and base editors thereof [patent_app_type] => utility [patent_app_number] => 18/457276 [patent_app_country] => US [patent_app_date] => 2023-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 40 [patent_no_of_words] => 24648 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18457276 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/457276
Engineered adenosine deaminases and base editors thereof Aug 27, 2023 Issued
Array ( [id] => 19158097 [patent_doc_number] => 20240150804 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => Demethylation of Reticuline and Derivatives Thereof with Fungal Cytochrome P450 [patent_app_type] => utility [patent_app_number] => 18/452054 [patent_app_country] => US [patent_app_date] => 2023-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452054 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/452054
Demethylation of Reticuline and Derivatives Thereof with Fungal Cytochrome P450 Aug 17, 2023 Pending
Array ( [id] => 18895503 [patent_doc_number] => 20240010988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => GENETICALLY MODIFIED PRIMARY CELLS FOR ALLOGENEIC CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/449625 [patent_app_country] => US [patent_app_date] => 2023-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 123114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18449625 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/449625
GENETICALLY MODIFIED PRIMARY CELLS FOR ALLOGENEIC CELL THERAPY Aug 13, 2023 Pending
Array ( [id] => 19521322 [patent_doc_number] => 12123034 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Methods and compositions for modulating a genome [patent_app_type] => utility [patent_app_number] => 18/447681 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 43 [patent_no_of_words] => 135076 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18447681 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/447681
Methods and compositions for modulating a genome Aug 9, 2023 Issued
Array ( [id] => 19311814 [patent_doc_number] => 12037617 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Methods and compositions for modulating a genome [patent_app_type] => utility [patent_app_number] => 18/447515 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 43 [patent_no_of_words] => 135420 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18447515 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/447515
Methods and compositions for modulating a genome Aug 9, 2023 Issued
Array ( [id] => 19291814 [patent_doc_number] => 12031162 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-09 [patent_title] => Methods and compositions for modulating a genome [patent_app_type] => utility [patent_app_number] => 18/447536 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 43 [patent_no_of_words] => 135790 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18447536 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/447536
Methods and compositions for modulating a genome Aug 9, 2023 Issued
Array ( [id] => 19113147 [patent_doc_number] => 20240124897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent [patent_app_type] => utility [patent_app_number] => 18/362867 [patent_app_country] => US [patent_app_date] => 2023-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18362867 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/362867
Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent Jul 30, 2023 Pending
Menu